Related Experiment Videos
Perftoran as a means modulating the functional activity of liver macrophages
A Yu Kovelenov1, A N Mikhal'tsov, A N Malkov
1Department of Infectious Diseases, S. M. Kirov Military Medical Academy, St. Petersburg, Russia.
Abstract:
Experiments on mice showed that perfluorocarbon emulsion Perftoran modulated phagocytic activity of liver macrophages (evaluated by LD50 for Salmonella typhi endotoxin and the rate of elimination of Chinese ink particles from the bloodflow). Phagocytic activity was suppressed for 3 days after injection of 10 mg/kg emulsion, but then increased above the control. Perftoran had a favorable impact on the course of experimental hepatitis in a model experiment based on hyperactivity of Kupffer cells. Perftoran virtually prevented the development of severe hepatitis after prophylactic injection and notably attenuated hepatocyte cytolysis when used as therapeutic mean.
Insights
Perftoran, a perfluorocarbon emulsion, initially suppressed then boosted macrophage activity in mice. This immune modulation favorably impacted experimental hepatitis, preventing severe disease and reducing liver cell damage.
Area of Science:
- Immunology
- Hepatology
- Biomedical Engineering
Background:
- Liver macrophages, specifically Kupffer cells, play a critical role in hepatic immune responses.
- Hyperactivity of Kupffer cells can contribute to the pathogenesis of liver diseases like hepatitis.
- Perfluorocarbon emulsions are artificial blood substitutes with potential immunomodulatory properties.
Purpose of the Study:
- To investigate the effects of perfluorocarbon emulsion Perftoran on the phagocytic activity of liver macrophages.
- To evaluate the therapeutic potential of Perftoran in a mouse model of experimental hepatitis characterized by Kupffer cell hyperactivity.
Main Methods:
- Mice were injected with Perftoran emulsion at a dose of 10 mg/kg.
- Phagocytic activity of liver macrophages was assessed using LD50 for Salmonella typhi endotoxin and Chinese ink particle clearance.
- Experimental hepatitis was induced to model Kupffer cell hyperactivity.
- Perftoran was administered both prophylactically and therapeutically.
Main Results:
- Perftoran initially suppressed macrophage phagocytic activity for 3 days, followed by a significant increase above control levels.
- Prophylactic administration of Perftoran largely prevented the development of severe experimental hepatitis.
- Therapeutic use of Perftoran notably attenuated hepatocyte cytolysis in the hepatitis model.
Conclusions:
- Perftoran exhibits biphasic immunomodulatory effects on liver macrophages, suppressing then enhancing phagocytic activity.
- Perftoran demonstrates significant protective and therapeutic potential against experimental hepatitis by modulating Kupffer cell function and reducing liver injury.